Literature DB >> 17728440

Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors.

James H Chin1, Li Ma, David MacTavish, Jack H Jhamandas.   

Abstract

Amyloid beta (Abeta) protein, a 39-43 amino acid peptide deposited in brains of individuals with Alzheimer's disease (AD), has been shown to interact directly with a number of receptor targets including neuronal nicotinic acetylcholine receptors (nAChRs) and glutamate receptors. In this study, we investigated the synaptic effects of Abeta(1-42) on glutamate-mediated neurotransmission in the diagonal band of Broca (DBB), a cholinergic basal forebrain nucleus. Glutamatergic miniature EPSCs (mEPSCs) were recorded using whole-cell patch-clamp recordings from identified cholinergic DBB neurons in rat forebrain slices. In 54% of DBB neurons, bath application of Abeta(1-42) (100 nM), but not Abeta(42-1) (inverse fragment), significantly increased the frequency of mEPSCs without affecting amplitude or kinetic parameters (rise or decay time). In 32% of DBB neurons, bath application of Abeta(1-42) significantly decreased only the frequency but not amplitude of mEPSCs. Application of dihydro-beta-erythroidine (DHbetaE) (an antagonist for the alpha4beta2 subtype of nAChRs) but not alpha-bungarotoxin (an antagonist for the alpha7 subtype of nAChRs) blocked Abeta(1-42)-mediated increases in mEPSC frequency. The Abeta(1-42)-mediated increase in glutamatergic transmission is thus presynaptic and mediated via non-alpha7 AChRs. In contrast, Abeta(1-42)-mediated decreases in mEPSC frequency could not be antagonized by either DHbetaE or alpha-bungarotoxin. However, the Abeta(1-42)-evoked depression in mEPSC frequency was antagonized by (RS)-alpha-methyl-4-carboxyphenyglycine, a nonselective group I/II metabotropic glutamate receptor antagonist. These observations provide further insight into the mechanisms whereby Abeta affects synaptic function in the brain and may be relevant in the context of synaptic failure observed in AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728440      PMCID: PMC6673123          DOI: 10.1523/JNEUROSCI.1843-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.

Authors:  H Y Wang; D H Lee; M R D'Andrea; P A Peterson; R P Shank; A B Reitz
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

2.  Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors.

Authors:  H Y Wang; D H Lee; C B Davis; R P Shank
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

3.  beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes.

Authors:  Kelly T Dineley; Karen A Bell; Duy Bui; J David Sweatt
Journal:  J Biol Chem       Date:  2002-04-30       Impact factor: 5.157

4.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 5.  Alzheimer's disease and Abeta toxicity: from top to bottom.

Authors:  D H Small; S S Mok; J C Bornstein
Journal:  Nat Rev Neurosci       Date:  2001-08       Impact factor: 34.870

6.  Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain.

Authors:  D Moechars; I Dewachter; K Lorent; D Reversé; V Baekelandt; A Naidu; I Tesseur; K Spittaels; C V Haute; F Checler; E Godaux; B Cordell; F Van Leuven
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

7.  beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice.

Authors:  D L Pettit; Z Shao; J L Yakel
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

8.  Cholinergic excitation of septohippocampal GABA but not cholinergic neurons: implications for learning and memory.

Authors:  M Wu; M Shanabrough; C Leranth; M Alreja
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

Review 9.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.

Authors:  D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

10.  Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice.

Authors:  J Larson; G Lynch; D Games; P Seubert
Journal:  Brain Res       Date:  1999-09-04       Impact factor: 3.252

View more
  27 in total

Review 1.  Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.

Authors:  Lian-Feng Lin; Huan-Min Luo
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

Review 2.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 3.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

4.  Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.

Authors:  Saak V Ovsepian; Valerie B O'Leary; Laszlo Zaborszky
Journal:  Neuroscientist       Date:  2015-05-22       Impact factor: 7.519

Review 5.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.

Authors:  Kou Takahashi; Joshua B Foster; Chien-Liang Glenn Lin
Journal:  Cell Mol Life Sci       Date:  2015-06-02       Impact factor: 9.261

6.  Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.

Authors:  Yongli Xie; Yibin Tan; Youbiao Zheng; Xiubo Du; Qiong Liu
Journal:  J Biol Inorg Chem       Date:  2017-05-13       Impact factor: 3.358

Review 7.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

8.  Local cholinergic-GABAergic circuitry within the basal forebrain is modulated by galanin.

Authors:  Joanne C Damborsky; Kathleen G Smith; Patricia Jensen; Jerrel L Yakel
Journal:  Brain Struct Funct       Date:  2016-08-05       Impact factor: 3.270

9.  Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis.

Authors:  Jason A Bailey; Bryan Maloney; Yuan-Wen Ge; Debomoy K Lahiri
Journal:  Gene       Date:  2011-06-25       Impact factor: 3.688

Review 10.  Therapeutic promise and principles: metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.